Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Families and children news

Show

From To
Vatican makes progress on pushing drug availability for kids with HIV

An initiative to identify and properly treat children living with HIV has gained new momentum as international organizations and pharmaceutical companies respond to a Vatican push to look past profit to doing the right thing.

Published
10 August 2018
From
Crux: Covering all things Catholic
AIDS 2018: The Story is Messy

It's already clear that the story from Amsterdam is that ending epidemic levels of new HIV diagnoses depends on building services and societies that recognize individuals as wonderful, wild, weird, whole people, with more specificity, respect and rigor than ever before. It also depends on activism, nasty women and their male allies, everyone demanding change, refusing to play nice.

Published
26 July 2018
From
AVAC
Pfizer and GSK's HIV/AIDS division, ViiV, prevents children with HIV from getting needed medicine

Despite ViiV pledging in November 2017 that it would expedite the availability of paediatric dolutegravir formulations where these are most critically needed, and despite repeated appeals from MSF and others, almost 18 months after paediatric formulations of dolutegravir were approved for use by the European Medicines Agency, the corporation has started the registration process in only three sub-Saharan African countries

Published
23 July 2018
From
Médecins Sans Frontières (MSF) International
Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.

Published
18 July 2018
From
MHRA
Dolutegravir preconception signal: time is up for shoddy surveillance

The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.

Published
16 July 2018
From
HIV i-Base
Dolutegravir: need to consider all pros and cons before switching in pregnancy

A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

Published
11 July 2018
From
HIV i-Base
Q&A: 'Global gag rule' hits Kenya's largest reproductive health organization

This month, Family Health Options Kenya shuttered its clinic in Kitengela, Kenya. The clinic, which had operated for more than four years, was closed in response to funding cuts due to the “global gag rule.” FHOK, which is the country’s first and largest sexual and reproductive health organization, provided 3.1 million reproductive health services in 2016.

Published
30 June 2018
From
Devex
Telling Children Their HIV Status: Interview With Dr Elizabeth Lowenthal

To learn more about the challenges associated with disclosure and how clinicians can support families throughout the process, Infectious Disease Advisor spoke with Elizabeth D. Lowenthal, MD, MSCE, assistant professor of pediatrics and epidemiology at the University of Pennsylvania Perelman School of Medicine, Philadelphia, and research director of the Global Health Research Affinity Group at Children's Hospital of Philadelphia.

Published
29 June 2018
From
Infectious Disease Advisor
How South African teenagers born HIV positive are navigating life in care

Fifteen years ago drugs were introduced that, for the first time, prevented mothers from transmitting the HIV virus to their babies. The drugs meant that children born to mothers infected with the virus could live long and fruitful lives despite being HIV positive. Since then researchers have studied the health issues facing children living with HIV and there’s a fairly good understanding about the medical challenges they face. But there’s still a lack of knowledge about the social issues these young people have to navigate.

Published
27 June 2018
From
The Conversation
Survey reveals women experience severe reproductive health issues

A new Public Health England (PHE) survey reveals that 31% of women experience severe reproductive health problems, but under half seek help.

Published
27 June 2018
From
GOV.UK
← First12345...55Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.